MedPath

TEDDY: Spores of Bacillus Clausii in Acute Diarrhoea in Children

Phase 3
Completed
Conditions
Diarrhea
Registration Number
NCT00265369
Lead Sponsor
Sanofi
Brief Summary

Primary objective:

* To demonstrate the efficacy of a Bacillus clausii probiotic strain compared to placebo in children suffering from acute diarrhoea and treated for 7 days.

Secondary objective:

* To evaluate the clinical safety of the Bacillus clausii probiotic strain versus placebo.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
420
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Duration of diarrhoea as counted from the first intake of the investigational product up to the first appearance of a loose stool followed by two-consecutive normal stools
Secondary Outcome Measures
NameTimeMethod
Number of infants/children with normal stools at D3, D4, D5, D6 and D7;Mean number of stools per day;Occurrence of vomiting episodes per day after enrolment;Parents'overall global assessment of efficacy at the end of the treatment;other safety criteria

Trial Locations

Locations (1)

Sanofi-Aventis

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath